Eikon Therapeutics, Inc. 8-K

What Happened Eikon Therapeutics (filed Form 8-K, Item 5.02 on June 10, 2026) announced that its Board appointed Ma. Fatima D. Francisco as a Class I director effective June 15, 2026. Ms. Francisco will serve until the company's 2027 annual meeting (or until her successor is elected) and will initially join the Board’s Compensation Committee. She has entered the company’s standard director indemnification agreement.

Key Details

• Appointment announced June 5, 2026; effective June 15, 2026; term through 2027 annual meeting.
• Compensation: eligible for 2026 non-employee director program — $50,000 annual retainer, paid quarterly and prorated.
• Equity award: option to buy 85,937 shares at $8.96 per share (Nasdaq close on grant date); vests in 48 substantially equal monthly installments, subject to continued service.
• No related person transactions or special arrangements were reported in connection with her selection.

Why It Matters This is a routine governance update — a new independent director joining the Board and Compensation Committee. The cash retainer and multi-year equity grant align Ms. Francisco’s incentives with shareholders and are typical for non-employee directors. There were no disclosed related-party deals or extraordinary payments, and the long monthly vesting schedule suggests the grant is intended to retain the director over time, not provide immediate financial impact.